Discounted Cash Flow Rating

Buy

Return on Equity Rating

Buy

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Strong Buy

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Buy

Insider Trading

Neutral

Wall Street Data Solutions Rating

Buy

A

Boston Scientific Corp. (BSX)

Surgical & Medical Instruments & Apparatus

https://www.bostonscientific.com

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

300 BOSTON SCIENTIFIC WAY
MARLBOROUGH, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/18/1992

Market Cap

114,887,229,450

Shares Outstanding

1,464,980,000

Weighted SO

1,464,982,777

Total Employees

N/A

Upcoming Earnings

10/24/2024

Similar Tickers

SYK --.--%

ABT --.--%

MDT --.--%

DXCM --.--%

EW --.--%

ZBH --.--%

ZIMV --.--%

STE --.--%

Beta

0.7860

Last Div

0.0000

Range

48.35-79.43

Chg

0.4350

Avg Vol

5807451

Mkt Cap

114887229450

Exch

NYSE

Country

US

Phone

508 683 4000

DCF Diff

42.9161

DCF

35.1939

Div Yield

0.0000

P/S

7.5445

EV Multiple

31.6912

P/FV

5.6320

Div Yield %

0.0000

P/E

62.8651

PEG

8.0518

Payout

0.0000

Current Ratio

1.6124

Quick Ratio

1.1447

Cash Ratio

0.5359

DSO

57.5256

DIO

190.2698

Op Cycle

247.7954

DPO

66.0983

CCC

181.6971

Gross Margin

0.6715

Op Margin

0.1784

Pretax Margin

0.1407

Net Margin

0.1198

Eff Tax Rate

0.1489

ROA

0.0492

ROE

0.0930

ROCE

0.0862

NI/EBT

0.8516

EBT/EBIT

0.7887

EBIT/Rev

0.1784

Debt Ratio

0.2848

D/E

0.5187

LT Debt/Cap

0.3061

Total Debt/Cap

0.3416

Int Coverage

9.8087

CF/Debt

0.2491

Equity Multi

1.8216

Rec Turnover

6.3450

Pay Turnover

5.5221

Inv Turnover

1.9183

FA Turnover

4.5227

Asset Turnover

0.4104

OCF/Share

1.7897

FCF/Share

1.1961

Cash/Share

2.0318

OCF/Sales

0.1728

FCF/OCF

0.6683

CF Coverage

0.2491

ST Coverage

1.6658

CapEx Coverage

3.0149

Div&CapEx Cov

3.0149

P/BV

5.6320

P/B

5.6320

P/S

7.5445

P/E

62.8651

P/FCF

65.3139

P/OCF

43.5900

P/CF

43.5900

PEG

8.0518

P/S

7.5445

EV Multiple

31.6912

P/FV

5.6320

DPS

0.0000

Latest Headlines (EST)

Benzinga Apr 04, 19:47 Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry GlobeNewswire Inc. Jan 18, 23:21 FST Corp.??????????????Chenghe Acquisition I Co.?????????? GlobeNewswire Inc. Jan 17, 01:15 Medical Lasers Market Size is Projected to Reach USD 12.02 billion by 2033, Growing at a CAGR of 9.10%: Straits Research Benzinga Jan 16, 10:00 Demystifying Boston Scientific: Insights From 10 Analyst Reviews MarketWatch Jan 09, 09:13 Here are Wall Street’s favorite stocks in the sector expected to grow profits the most in 2024 The Motley Fool Jan 08, 19:38 Why Axonics Stock Soared Today The Motley Fool Jan 08, 19:38 Why Axonics Stock Soared Today The Motley Fool Jan 08, 19:38 Why Axonics Stock Soared Today Zacks Investment Research Jan 01, 11:40 PBH vs. BSX: Which Stock Is the Better Value Option? Benzinga Dec 29, 12:00 Boston Scientific Stock: A Deep Dive Into Analyst Perspectives (8 Ratings) MarketWatch Dec 28, 07:46 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky MarketWatch Dec 28, 06:34 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky Benzinga Dec 15, 14:38 This Analyst Selects Enovis As Top Pick For 2024: Spotlight On EMPOWR Revision Launch Benzinga Dec 15, 14:38 This Analyst Selects Enovis As Top Pick For 2024: Spotlight On EMPOWR Revision Launch The Motley Fool Dec 14, 05:51 Billionaire Ken Griffin's Citadel Returned a Whopping $7 Billion to Investors -- These Are 3 of Its Biggest Holdings Benzinga Dec 13, 12:00 What 18 Analyst Ratings Have To Say About Boston Scientific Benzinga Nov 27, 13:00 Expert Ratings for Boston Scientific The Motley Fool Nov 25, 06:58 Could Ozempic Harm These 3 Medical Device Stocks? The Motley Fool Nov 25, 06:58 Could Ozempic Harm These 3 Medical Device Stocks? Benzinga Oct 30, 03:40 Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week

Revenue Product Segmentation